Cargando…

Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis

OBJECTIVE: We aimed to investigate the mortality rate and identify the predictors of death in patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. METHODS: Patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis were recruited from the Neurology Department of the First Hospit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Rui, Chen, Qingling, Zhang, Xinyue, Zhang, Hanyu, Lin, Weihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934853/
https://www.ncbi.nlm.nih.gov/pubmed/35320933
http://dx.doi.org/10.3389/fimmu.2022.845365
_version_ 1784671920582557696
author Zhong, Rui
Chen, Qingling
Zhang, Xinyue
Zhang, Hanyu
Lin, Weihong
author_facet Zhong, Rui
Chen, Qingling
Zhang, Xinyue
Zhang, Hanyu
Lin, Weihong
author_sort Zhong, Rui
collection PubMed
description OBJECTIVE: We aimed to investigate the mortality rate and identify the predictors of death in patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. METHODS: Patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis were recruited from the Neurology Department of the First Hospital of Jilin University from March 2015 to November 2021. The primary outcome variable was a binary variable of death vs. survival. The potential risk factors for mortality were evaluated. The mortality rates were determined, and the independent predictors of death were identified using multivariable logistic regression analysis. RESULTS: A total of 100 hospitalized patients with anti-NMDAR, anti-LGI1, or anti-GABABR encephalitis were included in the final analysis. Fifteen patients (15%) died during a median follow-up period of 18 months. The mortality rates were 10% for anti-NMDAR encephalitis, 2.8% for anti-LGI1 encephalitis, and 41.7% for anti-GABABR encephalitis. The multivariable analysis results showed that older age at onset [adjusted odds ratio (OR) = 1.017, 95% confidence interval (CI) = 1.009–1.136; p = 0.023] was independently associated with an increased risk of death. Antibody type was also associated with mortality. Patients with anti-GABABR encephalitis had 13.458-fold greater odds of dying than patients with anti-LGI1 encephalitis (adjusted OR = 13.458, 95% CI = 1.270–142.631; p = 0.031). CONCLUSION: The general mortality rate of anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis was 15%. Age at onset and type of autoimmune encephalitis antibody were independent predictors of death in these patients.
format Online
Article
Text
id pubmed-8934853
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89348532022-03-22 Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis Zhong, Rui Chen, Qingling Zhang, Xinyue Zhang, Hanyu Lin, Weihong Front Immunol Immunology OBJECTIVE: We aimed to investigate the mortality rate and identify the predictors of death in patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. METHODS: Patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis were recruited from the Neurology Department of the First Hospital of Jilin University from March 2015 to November 2021. The primary outcome variable was a binary variable of death vs. survival. The potential risk factors for mortality were evaluated. The mortality rates were determined, and the independent predictors of death were identified using multivariable logistic regression analysis. RESULTS: A total of 100 hospitalized patients with anti-NMDAR, anti-LGI1, or anti-GABABR encephalitis were included in the final analysis. Fifteen patients (15%) died during a median follow-up period of 18 months. The mortality rates were 10% for anti-NMDAR encephalitis, 2.8% for anti-LGI1 encephalitis, and 41.7% for anti-GABABR encephalitis. The multivariable analysis results showed that older age at onset [adjusted odds ratio (OR) = 1.017, 95% confidence interval (CI) = 1.009–1.136; p = 0.023] was independently associated with an increased risk of death. Antibody type was also associated with mortality. Patients with anti-GABABR encephalitis had 13.458-fold greater odds of dying than patients with anti-LGI1 encephalitis (adjusted OR = 13.458, 95% CI = 1.270–142.631; p = 0.031). CONCLUSION: The general mortality rate of anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis was 15%. Age at onset and type of autoimmune encephalitis antibody were independent predictors of death in these patients. Frontiers Media S.A. 2022-03-07 /pmc/articles/PMC8934853/ /pubmed/35320933 http://dx.doi.org/10.3389/fimmu.2022.845365 Text en Copyright © 2022 Zhong, Chen, Zhang, Zhang and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhong, Rui
Chen, Qingling
Zhang, Xinyue
Zhang, Hanyu
Lin, Weihong
Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis
title Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis
title_full Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis
title_fullStr Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis
title_full_unstemmed Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis
title_short Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis
title_sort risk factors for mortality in anti-nmdar, anti-lgi1, and anti-gababr encephalitis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934853/
https://www.ncbi.nlm.nih.gov/pubmed/35320933
http://dx.doi.org/10.3389/fimmu.2022.845365
work_keys_str_mv AT zhongrui riskfactorsformortalityinantinmdarantilgi1andantigababrencephalitis
AT chenqingling riskfactorsformortalityinantinmdarantilgi1andantigababrencephalitis
AT zhangxinyue riskfactorsformortalityinantinmdarantilgi1andantigababrencephalitis
AT zhanghanyu riskfactorsformortalityinantinmdarantilgi1andantigababrencephalitis
AT linweihong riskfactorsformortalityinantinmdarantilgi1andantigababrencephalitis